Table 3 Summary of the results
From: Expression of the Tpl2/Cot oncogene in human T-cell neoplasias
Patient no. | Immunophenotype | Serum TNF-α (pg/ml) | Tpl2/Cot (fold increase) |
|---|---|---|---|
1 | CD3+, CD4+, CD7- | 1.7 | 0.6 |
2 | CD3+, CD8+, CD56+, CD57+, TCRαβ+ | 1.9 | 3.9 |
3 | CD3+, CD8+, CD16, 56-, CD57+, TCRαβ+ | 1.8 | 4 |
4 | CD3+, CD4+, CD5+, CD7+ | 1.5 | 0.7 |
5 | CD3+, CD4+, CD7- | 1.9 | 1.2 |
6 | TdT+, CD5+, CD2+ | 2.5 | 1.7 |
7 | CD3+CD4+CD25-TCRγ+ | 3.8 | 1.8 |
8 | CD2+, CD3-, CD16+, CD56-, CD57-, TCR- | 6.2 | 5.2 |
9 | TdT+, CD2+, CD3+, CD7+, CD4-, CD8- | 2.6 | 0.3 |
10 | 2 populations: a) T-LGL CD3+, CD8+, CD56+, CD57+, TCR γ+ b) NK CD2+, CD3-, CD16, 56+, 57- | 1.9 | 5 |
11 | CD3+, CD4+, CD7-, CD25-, TCRαβ+ | 1.2 | 1.1 |
12 | TdT+, cCD3+, CD7+, CD4-CD8- | 1.5 | 1.2 |